{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:42:47Z","timestamp":1792215767600,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1C1C1011178"],"award-info":[{"award-number":["NRF-2019R1C1C1011178"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2023-00262969"],"award-info":[{"award-number":["RS-2023-00262969"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.10.009","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:19:09Z","timestamp":1792113549000},"page":"83-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure"],"prefix":"10.1016","volume":"214","author":[{"given":"Sanghoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-A","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Kyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.10.009_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2022.11.031","article-title":"The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma","volume":"169","author":"Di Dio","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"10333","key":"10.1016\/j.ygyno.2026.10.009_bb0010","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ygyno.2026.10.009_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246155","article-title":"Pharmacological treatment of advanced, persistent or metastatic endometrial cancer: state of the art and perspectives of clinical research for the special issue \"Diagnosis and management of endometrial cancer\"","volume":"13","author":"Gadducci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.ygyno.2026.10.009_bb0020","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.009_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ygyno.2026.10.009_bb0030","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/jama.2026.2248","article-title":"Endometrial cancer: a review","volume":"335","author":"Mager","year":"2026","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.009_bb0035","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2026.10.009_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7447","key":"10.1016\/j.ygyno.2026.10.009_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.009_bb0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.009_bb0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/AOG.0000000000006080","article-title":"Molecular characterization and clinical implications of endometrial cancer","volume":"146","author":"Secord","year":"2025","journal-title":"Obstet. Gynecol."},{"issue":"19","key":"10.1016\/j.ygyno.2026.10.009_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911684","article-title":"TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives","volume":"23","author":"Arciuolo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2026.10.009_bb0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2024.04.008","article-title":"Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): a critical reappraisal with comments on FIGO 2023 staging","volume":"186","author":"Espinosa","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.10.009_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2025.03.006","article-title":"The genomic landscape of distant metastatic endometrial cancer","volume":"195","author":"Zammarrelli","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.009_bb0075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2021.02.015","article-title":"Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer","volume":"161","author":"Da Cruz Paula","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2026.10.009_bb0080","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41388-022-02368-w","article-title":"Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer","volume":"41","author":"Datta","year":"2022","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.009_bb0085","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/SLA.0000000000002450","article-title":"Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases","volume":"269","author":"Chun","year":"2019","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2026.10.009_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ygyno.2026.10.009_bb0095","article-title":"Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS\/TP53 mutation status and tumor-sideness in colorectal cancers","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.ygyno.2026.10.009_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14145135","article-title":"Prognostic impact of KRAS-TP53 co-mutations in patients with early-stage non-small cell lung cancer: a single-center retrospective study","volume":"14","author":"Motta","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2026.10.009_bb0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2024.10.026","article-title":"KRAS mutations in endometrial cancers: possible prognostic and treatment implications","volume":"191","author":"Kilowski","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.009_bb0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.21873\/anticanres.13145","article-title":"The role of KRAS in endometrial cancer: a mini-review","volume":"39","author":"Sideris","year":"2019","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.009_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030801","article-title":"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features","volume":"7","author":"Byron","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ygyno.2026.10.009_bb0120","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-20-4436","article-title":"Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas","volume":"27","author":"Momeni-Boroujeni","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2026.10.009_bb0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41588-019-0572-y","article-title":"Identification of cancer driver genes based on nucleotide context","volume":"52","author":"Dietlein","year":"2020","journal-title":"Nat. Genet."},{"issue":"14","key":"10.1016\/j.ygyno.2026.10.009_bb0130","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-23-2819","article-title":"Clinical and genomic landscape of RAS mutations in gynecologic cancers","volume":"30","author":"Son","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.10.009_bb0135","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1186\/s12885-024-12776-8","article-title":"Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis","volume":"24","author":"Tang","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.10.009_bb0140","first-page":"3233","article-title":"Prognostic value of KRAS\/TP53\/PIK3CA in non-small cell lung cancer","volume":"17","author":"Zhao","year":"2019","journal-title":"Oncol. Lett."},{"issue":"40","key":"10.1016\/j.ygyno.2026.10.009_bb0145","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1038\/s41388-025-03536-4","article-title":"Coexistence of P53 and KRAS mutations enhances ERK1\/2 signaling by inducing EGR1 expression through mutp53 and c-JUN interaction","volume":"44","author":"Wang","year":"2025","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ygyno.2026.10.009_bb0150","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/cas.15328","article-title":"Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma","volume":"113","author":"Kobayashi Kato","year":"2022","journal-title":"Cancer Sci."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:12:37Z","timestamp":1792213957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"alternative-id":["S0090825826021608"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}